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LETTERS TO THE EDITORThe Frequency of Rare
EGFR Mutations Is Higher
than that of Classical Ones
How Come?To the Editor:
Because only a few studies have been published on
this topic, we have read with great interest the article
of Lohinai et al. titled, “Distinct Epidemiology and
Clinical Consequence of Classic versus Rare EGFR
Mutations in Lung Adenocarcinoma.”1 The authors
compare the epidemiology and clinical consequence of
classical and rare epidermal growth factor receptor
gene (EGFR) mutations in a cohort of Hungarian pa-
tients with lung adenocarcinoma. They deﬁned clas-
sical EGFR mutations as the combination of the L858R
point mutation in exon 21 and exon 19 microdeletions,
rare EGFR mutations as nonclassical mutation in the
tyrosine kinase–coding region (exons 18–21) where
amino acid change occurs, and synonymous EGFR
mutations as nucleotide changes without protein
alterations.
In their article, Lohinai et al. reported that classical
and rare nonsynonymous EGFR mutations were iden-
tiﬁed in 5% and 6% of patients, respectively. This
ﬁnding is quite surprising for several reasons. First, the
incidence of rare EGFR mutations in this study is much
higher than in similar studies of whites (0.8%–
4.4%).2–4 Lohinai et al. justiﬁed this high rate of rare
EGFR mutations by the facts that exon 20 sequencing
was also performed in three-fourths of patients and
40% of all patients with Kirsten rat sarcoma viral
oncogene homolog (KRAS) mutations underwent EGFR
analysis as well. In our opinion, these arguments
cannot fully explain the high rate of rare EGFR mutation
because most of the recent studies in whites that have
reported the frequency of EGFR mutation subtypes
have also included exon 20 analysis2–4 and, on the
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were found in the present study.
Second, the fact that the proportion of rare EGFR
mutations is higher than that of classical ones, as found
in this series, seems inadequate by deﬁnition. Indeed, in
studies of both whites and Asians, it has been reported
that about 90% of all lung adenocarcinoma–associated
EGFR mutations are classical ones whereas the propor-
tion of rare EGFR mutations does not usually exceed
10% to 15%.3–5 Of note, in our retrospective study that
was recently published in this journal, the rate of rare
EGFR mutations (exon 20 analysis was also performed)
was 10% of all mutations.6
Finally, we agree with the authors’ statement with
regard to the fact that some of their results need to be
conﬁrmed in a prospective setting because in any
retrospective study, some sources of bias cannot be
ruled out.
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